CustomerValidation
- •JAutoimmun.2016Feb;67:90-101.
- •JBoneMinerRes.2015Nov;30(11):1959-68.
- •FASEBJ.2015Sep;29(9):3737-49.
- •EnvironToxicolPharmacol.2014Sep;38(2):374-8.
- •ActaBiochimBiophysSin(Shanghai).2017Apr1;49(4):302-310.
Description | EMD638683isahighlyselectiveSGK1inhibitorwithIC50of3μM. |
---|---|
IC50&Target | IC50:3μM(SGK1)[1] |
InVitro | EMD638683isaSGK1inhibitor.EMD638683inhibitstheNDRG1(N-Mycdownstream-regulatedgene1)phosphorylation,aneffectrequiring3.35±0.32μMEMD638683inthecellculturemediumforhalfmaximaleffect(IC50).EMD638683hasalsoaninhibitoryeffectoncAMP-dependentproteinkinase(PKA),mitogen-andstress-activatedproteinkinase1(MSK1),proteinkinaseC-relatedkinase2(PKR2),andtheSGKisoformsSGK2andSGK3[1].Inboth,controlandEMD638683(50µM)-treatedCaCo-2cells,rADIationsignificantlyincreasesthepercentageofCaCo-2cellsundergoinglateapoptosis.EMD638683treatmentalonetendstoenhancethepercentageofapoptoticCaCo-2cells.FollowingradiationthepercentageofapoptoticEMD638683-treatedCaCo-2cellsissignificantlyhigherthanthepercentageofapoptoticcontrolcells.Thus,EMD638683treatmentsignificantlyaugmentstheapoptosisfollowingradiation[2]. |
InVivo | ThecolonissignificantlylongerandthecolonweightsignificantlylowerinEMD638683-treatedmicethaninplacebo-treatedmice,afindingpointingtoaninfluenceofEMD638683ontumorgrowthfollowingchemicalcarcinogenesis.Inaddition,thestomachweightissignificantlylowerintheEMDtreatedgroup.Mostimportantly,thenumberofdevelopingtumorsfollowingcarcinogenictreatmentissignificantlybluntedbyEMD638683treatment[2].EMD638683(20mg/kg,intragastrically)preventsprogressionofmonocrotaline(MCT)-inducedpulmonaryvascularremodelinginrats.HemodynamiccharacteristicsshowthatEMD638683treatmentattenuatesrightventricularsystolicpressure(RVSP)(15.8±2.5vs.28.2±3.1mmHg;P<0.05; n="6)" and="" right="" ventricular="" hypertrophy="" index="" (rvhi)="" (0.27±0.02="" vs.="">0.05;><0.05; n="6)" compare="" to="" vehicle-dosed="">0.05;>[3]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [2] | EMD638683isdissolvedinDMSOandstored,andthendilutedwithappropriatemediabeforeuse[2]. Coloncarcinoma(CaCo-2)cellsaregrownincompleteDMEMmediumcontaining10%fetalcalfserum,1%sodiumpyruvate,1%penicillin-streptomycinand1%non-essentialaminoacidsunderstandardcultureconditions(37°C,5%CO2).105cellsareseededin6wellplatesandculturedwithfreshculturemediumfor24h,afterwhichEMD638683(50µM)isappliedfor24hours.Forcomparison,thecellsaretreatedwiththesolvent(0.2μLDMSO)andonesolventcontrolisanalysedwitheachsetofexperiments.Thecellsaresubsequentlyexposedto3.18minradiation(3Gray).Afterfurtherincubationfor72hinthepresenceorabsenceofEMD638683(50µM)thecellsareanalyzedutilizingflowcytometry[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdmiNISTration [3] | EMD638683issynthesizedbyHaoyuan(Shanghai,China)anddissolvedin1%DMSO[3]. RatandMice[3] | ||||||||||||||||
References |
|
MolecularWeight | 364.34 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₁₈H₁₈F₂N₂O₄ | ||||||||||||
CASNo. | 1181770-72-8 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO EMD638683isfixedin4%formaldehyde[4]. *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> | ||||||||||||
References |
|
Purity:99.74%